Timing To Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy For Rectal Cancer: A Multicenter Randomized Controlled Trial - Biomarkers SubStudy
The TiMiSNAR-miRNA study aims to identify and validate microRNAs as potential blood-based biomarkers for assessing treatment response in locally advanced rectal cancer. This could address a significant unmet need in the oncology market, where current biomarkers (CEA and ctDNA) have limitations. If successful, the findings could lead to enhanced patient stratification and monitoring, potentially improving treatment outcomes and reducing healthcare costs. The study's focus on non-invasive liquid biopsies aligns with the growing trend towards personalized medicine and could position the sponsor favorably in the competitive landscape of cancer diagnostics.
Indication: Rectal Cancer
Modality: RNA therapy
Target: MicroRNAs (miRNAs) as blood-based biomarkers for monitoring tumor response in rectal cancer post-neoadjuvant chemoradiotherapy.
Sponsor: Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 14, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: MicroRNAs (miRNAs) as blood-based biomarkers for monitoring tumor response in rectal cancer post-neoadjuvant chemoradiotherapy.
View original source fields
Condition raw: Rectal Cancer
Condition normalized: Rectal Cancer
Modality raw: RNA therapy
Modality normalized: RNA therapy
Target raw: MicroRNAs (miRNAs) as blood-based biomarkers for monitoring tumor response in rectal cancer post-neoadjuvant chemoradiotherapy.
Target normalized: MicroRNAs (miRNAs) as blood-based biomarkers for monitoring tumor response in rectal cancer post-neoadjuvant chemoradiotherapy.